+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and early effects of the drug combination ZE50-0134 and Azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia AML. This open-label Phase 1b study focuses on patients who have not responded to previous treatments or whose disease has returned. The study aims to find the best dose and schedule of this combination therapy using a 3 3 dose escalation design before expanding to a larger group of patients. The study has two parts first, a dose escalation phase where different doses of Lonitoclax ZE50-0134 combined with Azacitidine are tested to find the biologically effective dose. Then, an expansion phase will enroll about 30 patients divided into two groups receiving different dose levels to determine the recommended phase 2 dose. Treatments include oral capsules of ZE50-0134 given once or twice daily and Azacitidine administered at 75 mgm2 daily for 7 days. Adjustments to doses may occur based on tolerability and safety findings. Participants will be involved in up to 24 cycles of treatment, each lasting 4 weeks. They will undergo assessments including safety monitoring and measuring responses to treatment. Researchers will evaluate how well patients blood counts recover, monitor side effects, and track event-free survival and remission duration. Close monitoring during treatment helps understand the best dosing and safety profile of the combination. The total study duration may extend up to nearly two years, including follow-up periods.

Age: 18Years +All GendersPhase 1
6 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Age: 18Years +All GendersPhase 3
28 locations
O

Actively Recruiting

Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.

Age: 18Years +MALE
28 locations
S

Actively Recruiting

Researchers are evaluating the drug 4-MUST to understand its effectiveness, safety, and tolerability in treating patients with chronic cholecystitis and biliary dyskinesia. This study compares different doses of 4-MUST with a placebo to see how well the drug reduces upper abdominal pain and gastrointestinal symptoms. The trial is a phase 2, prospective, randomized, double-blind, placebo-controlled study designed to provide detailed insight into the drugs impact on these digestive conditions. Participants will be randomly assigned to one of four groups. One group receives 1 tablet of 4-MUST 128 mg plus 2 placebo tablets three times daily, another receives 2 tablets of 4-MUST 256 mg plus 1 placebo tablet three times daily, a third group takes 3 tablets of 4-MUST 384 mg three times daily, and the last group receives 3 placebo tablets three times daily. The treatment lasts for 29 days, with doses given three times a day, followed by assessment and monitoring. During the study, participants will undergo regular evaluations including pain measurement using a Visual Analog Scale VAS, gastrointestinal symptom rating via questionnaires, and quality of life assessments with the SF-36 questionnaire. Safety will be monitored through adverse event tracking, physical examinations, vital signs, laboratory tests, and electrocardiograms at multiple time points throughout the 29-day period and up to day 36. These thorough assessments aim to capture the drugs effects and tolerability over the course of treatment.

Age: 18Years - 70YearsAll GendersPhase 2
17 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness and safety of different doses of the drug Grammidin with anesthetic, delivered as a metered dose topical spray, for treating acute infectious and inflammatory diseases of the pharynx. These conditions include acute pharyngitis, nasopharyngitis, and exacerbation of chronic pharyngitis. The study compares Grammidin spray with Septolete Total lozenges as an active comparator in a Phase 2 randomized trial. Participants are assigned to one of three groups one group receives Grammidin spray with 2 sprays every 6 hours three times daily for 7 days, another group receives Grammidin spray with 4 sprays on the same schedule, and the third group takes Septolete Total lozenges 1 lozenge every 6 hours, up to 3 lozenges daily for 7 days. Treatments are taken under fed conditions. The study is open-label, multicenter, and parallel-group. During the 8-day study period, participants attend visits on Day 1, Day 5, and Day 8 for assessments including sore throat severity measured by Visual Analog Scale VAS and the Clinical Symptom Severity Scale. Researchers monitor clinical symptoms, inflammation signs, and intoxication syndrome. Safety is evaluated through recording adverse events, vital signs, physical examinations, and multiple laboratory tests such as blood counts, blood chemistry, and urinalysis. The study tracks treatment adherence and overall patient outcomes over the three visits.

Age: 18Years - 75YearsAll GendersPhase 2
12 locations